Norges Bank
CYTK icon

Norges Bank’s Cytokinetics CYTK Stock Holding History

Norges Bank’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86.5M Buy
+1,015,522
New +$72.9M 0.01% 825
2026
Q1 		– Sell
-807,070
Closed -$51.3M – 374
2025
Q4 		$51.3M Buy
+807,070
New +$50.2M 0.01% 1008
2025
Q3 		– Sell
-1,184,072
Closed -$39.1M – 418
2025
Q2 		$39.1M Buy
1,184,072
+7,153
+0.6% +$249K ﹤0.01% 1048
2025
Q1 		$47.3M Buy
1,176,919
+187,198
+19% +$8.6M 0.01% 961
2024
Q4 		$46.6M Sell
989,721
-2,916
-0.3% -$151K 0.01% 989
2024
Q3 		$52.4M Buy
992,637
+192,973
+24% +$10.8M 0.01% 952
2024
Q2 		$43.3M Sell
799,664
-183,097
-19% -$11.1M 0.01% 961
2024
Q1 		$68.9M Buy
982,761
+260,532
+36% +$20.2M 0.01% 794
2023
Q4 		$60.3M Sell
722,229
-107,278
-13% -$3.88M 0.01% 819
2023
Q3 		$24.4M Buy
829,507
+78,057
+10% +$2.6M 0.01% 1151
2023
Q2 		$24.5M Buy
751,450
+13,291
+2% +$492K ﹤0.01% 1169
2023
Q1 		$26M Sell
738,159
-101,197
-12% -$4.13M 0.01% 1149
2022
Q4 		$38.5M Buy
839,356
+15,860
+2% +$682K 0.01% 919
2022
Q3 		$39.9M Buy
823,496
+70,762
+9% +$3.41M 0.01% 867
2022
Q2 		$29.6M Buy
752,734
+156,355
+26% +$6.29M 0.01% 1039
2022
Q1 		$22M Buy
+596,379
New +$21.2M ﹤0.01% 1352
2020
Q4 		– Sell
-207,200
Closed -$4.49M – 2125
2020
Q3 		$4.49M Hold
207,200
– – ﹤0.01% 1880
2020
Q2 		$4.88M Buy
+207,200
New +$3.89M ﹤0.01% 1867
2017
Q1 		– Sell
-80,321
Closed -$976K – 2148
2016
Q4 		$976K Buy
+80,321
New +$852K ﹤0.01% 2055

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank's CYTK Position: Q2 2026 in Review

Norges Bank opened a new position in Cytokinetics (CYTK) in Q2 2026: 1,015,522 shares worth $86.5M. The stake represents 0.01% of the portfolio and ranks #825 among its holdings. This is a return to the name: Norges Bank previously reported a position in CYTK as recently as Q4 2025.

Norges Bank first reported a position in CYTK in Q4 2016 and has held it in 19 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Norges Bank held 1,015,522 shares of Cytokinetics worth $86.5M as of Q2 2026.
  • Cytokinetics was a new Norges Bank position in Q2 2026.
  • Cytokinetics made up 0.01% of Norges Bank's portfolio in Q2 2026, its #825 holding.
  • Norges Bank first reported a position in Cytokinetics in Q4 2016 and has held it in 19 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Norges Bank's 13F filing for Q2 2026, filed 12 Aug 2026.